Why is Titan Biotech falling/rising?

As of 21-Aug, Titan Biotech Ltd is currently priced at 454.10, reflecting a decrease of 5.9 or 1.28%. The stock has underperformed its sector by 1.3% today, and its delivery volume has fallen significantly by 24.86% compared to the 5-day average, indicating a decline in investor participation. Over the past week, the stock has decreased by 3.61%, while its year-to-date performance shows a substantial drop of 38.03%. Despite having a high return on equity (ROE) of 25.08% and a low debt-to-equity ratio of 0.05, the company faces challenges with poor long-term growth, as evidenced by a -3.08% annual decline in operating profit over the last five years and a significant drop in profits of 12.3% over the past year. In the broader market context, the Sensex has increased by 1.74% over the past week, contrasting sharply with Titan Biotech's decline. The stock's performance has been notably worse than the market, with a one-year return of -22.11% compared to the BSE500's negative return of -1.56%. This underperformance, coupled with a high price-to-book value ratio of 2.4, suggests that the stock is trading at a premium compared to its peers, further contributing to investor hesitance. Overall, the combination of declining investor interest, poor growth metrics, and high valuation relative to peers has led to the stock's recent downward movement.